133 related articles for article (PubMed ID: 1619986)
21. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
[TBL] [Abstract][Full Text] [Related]
22. The impact of forearm immobilization and acipimox administration on muscle amino acid metabolism and insulin sensitivity in healthy, young volunteers.
Dirks ML; Jameson TSO; Andrews RC; Dunlop MV; Abdelrahman DR; Murton AJ; Wall BT; Stephens FB
Am J Physiol Endocrinol Metab; 2024 Mar; 326(3):E277-E289. PubMed ID: 38231001
[TBL] [Abstract][Full Text] [Related]
23. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis.
Petrides AS; Groop LC; Riely CA; DeFronzo RA
J Clin Invest; 1991 Aug; 88(2):561-70. PubMed ID: 1864966
[TBL] [Abstract][Full Text] [Related]
24. Effect of acute inhibition of lipolysis on operation of the glucose-fatty acid cycle in hepatic cirrhosis.
Farrer M; Fulcher GR; Johnson AJ; Record CO; Alberti KG
Metabolism; 1992 May; 41(5):465-70. PubMed ID: 1588824
[TBL] [Abstract][Full Text] [Related]
25. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of lipolysis in Type 2 diabetes normalizes glucose disposal without change in muscle glycogen synthesis rates.
Lim EL; Hollingsworth KG; Smith FE; Thelwall PE; Taylor R
Clin Sci (Lond); 2011 Aug; 121(4):169-77. PubMed ID: 21388348
[TBL] [Abstract][Full Text] [Related]
27. Interaction of lipid and carbohydrate metabolism after infusions of lipids or of lipid lowering agents: lack of a direct relationship between free fatty acid concentrations and glucose disposal.
Kleiber H; Munger R; Jallut D; Tappy L; Felley C; Golay A; Frascarolo P; Jéquier E; Felber JP
Diabete Metab; 1992; 18(2):84-90. PubMed ID: 1511757
[TBL] [Abstract][Full Text] [Related]
28. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
Lanzi R; Luzi L; Caumo A; Andreotti AC; Manzoni MF; Malighetti ME; Sereni LP; Pontiroli AE
Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
[TBL] [Abstract][Full Text] [Related]
29. Effects of Acipimox on the metabolism of free fatty acids and very low lipoprotein triglyceride.
Hannah JS; Bodkin NL; Paidi MS; Anh-Le N; Howard BV; Hansen BC
Acta Diabetol; 1995 Dec; 32(4):279-83. PubMed ID: 8750769
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of insulin resistance after kidney transplantation.
Ekstrand A; Ahonen J; Grönhagen-Riska C; Groop L
Transplantation; 1989 Oct; 48(4):563-8. PubMed ID: 2678633
[TBL] [Abstract][Full Text] [Related]
31. Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects.
Liang H; Tantiwong P; Sriwijitkamol A; Shanmugasundaram K; Mohan S; Espinoza S; Defronzo RA; Dubé JJ; Musi N
J Physiol; 2013 Jun; 591(11):2897-909. PubMed ID: 23529132
[TBL] [Abstract][Full Text] [Related]
32. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans.
Nuutila P; Knuuti MJ; Raitakari M; Ruotsalainen U; Teräs M; Voipio-Pulkki LM; Haaparanta M; Solin O; Wegelius U; Yki-Järvinen H
Am J Physiol; 1994 Dec; 267(6 Pt 1):E941-6. PubMed ID: 7810638
[TBL] [Abstract][Full Text] [Related]
33. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure.
Nielsen S; Møller N; Christiansen JS; Jørgensen JO
Diabetes; 2001 Oct; 50(10):2301-8. PubMed ID: 11574412
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM.
Puhakainen I; Yki-Järvinen H
Diabetes; 1993 Dec; 42(12):1694-9. PubMed ID: 8243814
[TBL] [Abstract][Full Text] [Related]
36. Effects of phlorizin and acipimox on insulin resistance in STZ-diabetic rats.
Kim YW; Kim JY; Lee SK
J Korean Med Sci; 1995 Feb; 10(1):24-30. PubMed ID: 7598820
[TBL] [Abstract][Full Text] [Related]
37. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function.
Halbirk M; Nørrelund H; Møller N; Schmitz O; Gøtzsche L; Nielsen R; Nielsen-Kudsk JE; Nielsen SS; Nielsen TT; Eiskjær H; Bøtker HE; Wiggers H
Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1220-5. PubMed ID: 20709866
[TBL] [Abstract][Full Text] [Related]
38. Free fatty acids increase hepatic glycogen content in obese males.
Allick G; Sprangers F; Weverling GJ; Ackermans MT; Meijer AJ; Romijn JA; Endert E; Bisschop PH; Sauerwein HP
Metabolism; 2004 Jul; 53(7):886-93. PubMed ID: 15254882
[TBL] [Abstract][Full Text] [Related]
39. Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
Park KS; Kim CH; Lee MK; Shin CS; Park DJ; Kim SY; Cho BY; Lee HK
Metabolism; 1999 Oct; 48(10):1318-21. PubMed ID: 10535397
[TBL] [Abstract][Full Text] [Related]
40. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM.
Widén EI; Eriksson JG; Groop LC
Diabetes; 1992 Mar; 41(3):354-8. PubMed ID: 1551495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
